Literature DB >> 2029269

The 'A rule' of mutagen specificity: a consequence of DNA polymerase bypass of non-instructional lesions?

B S Strauss1.   

Abstract

The replicative bypass of lesions in DNA and the induction of mutations by agents which react with DNA to produce damaged bases can be understood on the basis of a simple kinetic model. Bypass can be analyzed by separately considering three processes: a) addition of a base opposite a lesion, b) a proofreading excision process, and c) a rate limiting elongation step. Adenine nucleotides are preferentially added opposite many lesions making it possible to predict mutational specificity. Replicative bypass (translesion synthesis) is dependent on modulation of proofreading exonuclease activity but loss of exonuclease activity alone is not sufficient to ensure bypass. Frameshift mutation is the result of the failure of translesion synthesis accompanied by rearrangement of the template, particularly at repetitive sites.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2029269     DOI: 10.1002/bies.950130206

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  87 in total

1.  A method for detecting abasic sites in living cells: age-dependent changes in base excision repair.

Authors:  H Atamna; I Cheung; B N Ames
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

2.  Sulfolobus solfataricus P2 DNA polymerase IV (Dpo4): an archaeal DinB-like DNA polymerase with lesion-bypass properties akin to eukaryotic poleta.

Authors:  F Boudsocq; S Iwai; F Hanaoka; R Woodgate
Journal:  Nucleic Acids Res       Date:  2001-11-15       Impact factor: 16.971

3.  Roles of yeast DNA polymerases delta and zeta and of Rev1 in the bypass of abasic sites.

Authors:  L Haracska; I Unk; R E Johnson; E Johansson; P M Burgers; S Prakash; L Prakash
Journal:  Genes Dev       Date:  2001-04-15       Impact factor: 11.361

4.  Difference between deoxyribose- and tetrahydrofuran-type abasic sites in the in vivo mutagenic responses in yeast.

Authors:  Chie Otsuka; Sachi Sanadai; Yasuhiro Hata; Hisanori Okuto; Vladimir N Noskov; David Loakes; Kazuo Negishi
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

5.  Error-prone lesion bypass by human DNA polymerase eta.

Authors:  Y Zhang; F Yuan; X Wu; O Rechkoblit; J S Taylor; N E Geacintov; Z Wang
Journal:  Nucleic Acids Res       Date:  2000-12-01       Impact factor: 16.971

6.  Mechanism of translesion transcription by RNA polymerase II and its role in cellular resistance to DNA damage.

Authors:  Celine Walmacq; Alan C M Cheung; Maria L Kireeva; Lucyna Lubkowska; Chengcheng Ye; Deanna Gotte; Jeffrey N Strathern; Thomas Carell; Patrick Cramer; Mikhail Kashlev
Journal:  Mol Cell       Date:  2012-03-08       Impact factor: 17.970

7.  Lesion bypass DNA polymerases replicate across non-DNA segments.

Authors:  Ayelet Maor-Shoshani; Vered Ben-Ari; Zvi Livneh
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

8.  Mechanism of nucleotide incorporation opposite a thymine-thymine dimer by yeast DNA polymerase eta.

Authors:  M Todd Washington; Louise Prakash; Satya Prakash
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-03       Impact factor: 11.205

9.  The Nonbulky DNA Lesions Spiroiminodihydantoin and 5-Guanidinohydantoin Significantly Block Human RNA Polymerase II Elongation in Vitro.

Authors:  Marina Kolbanovskiy; Moinuddin A Chowdhury; Aditi Nadkarni; Suse Broyde; Nicholas E Geacintov; David A Scicchitano; Vladimir Shafirovich
Journal:  Biochemistry       Date:  2017-06-07       Impact factor: 3.162

10.  Structure of DNA polymerase beta with a benzo[c]phenanthrene diol epoxide-adducted template exhibits mutagenic features.

Authors:  Vinod K Batra; David D Shock; Rajendra Prasad; William A Beard; Esther W Hou; Lars C Pedersen; Jane M Sayer; Haruhiko Yagi; Subodh Kumar; Donald M Jerina; Samuel H Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.